The U.S. Food and Drug Administration has granted its first-ever license for a freeze-dried plasma product, marking a major advance in emergency transfusion medicine. The newly approved product, Ezplaz Freeze Dried Plasma, was developed by Vascular Solutions, a subsidiary of Teleflex, and is authorized for adult patients requiring plasma when conventional options aren’t accessible.
What sets Ezplaz apart is its practicality in high-stress, low-resource environments. Traditional plasma must be kept frozen and thawed before administration—a process that can be difficult or impossible in combat zones, disaster zones, or rural areas far from hospital facilities. Ezplaz, by contrast, is shelf-stable at room temperature, withstands temperature swings, and can be reconstituted quickly. Its packaging in a flexible plastic pouch instead of glass also lowers the chance of damage during transport.
According to CBER’s acting director, the approval fills a critical gap for patients suffering severe blood loss in settings without ready access to standard hospital resources, including military personnel deployed in remote areas. The agency’s blood research division added that the decision reflects a balance between fostering innovation and upholding strict safety and efficacy standards.
Each Ezplaz kit comes fully equipped with the freeze-dried plasma unit, sterile water for reconstitution, and the necessary transfer and transfusion equipment—designed as an all-in-one solution for urgent care.
The product’s roots trace back to a 2017 federal law that established a partnership between the Department of Defenseand the FDA to accelerate development of treatments for conditions affecting service members. FDA guidance issued in 2019 laid the groundwork for manufacturers pursuing dried plasma technology.
Regulators state that Ezplaz’s safety profile aligns with existing plasma products, though standard transfusion risks still apply.
Written By: Sayan Das
Graphics by: Pramit Hazra
